Amarin Asks Fed. Circ. To Undo Heart Drug IP Decision
Amarin Pharma Inc. has asked the Federal Circuit to reverse a Delaware federal judge's finding that Hikma Pharmaceuticals USA Inc.'s generic heart drug does not infringe patents underlying Amarin drug Vascepa....To view the full article, register now.
Already a subscriber? Click here to view full article